Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept

Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=ipamorelin,ghrp-2

Side-by-side comparison of Ipamorelin, GHRP-2
IpamorelinGHRP-2
Identity
ClassGrowth hormone secretagogue; ghrelin receptor (GHS-R1a) agonist. Synthetic pentapeptide containing unnatural amino acidsGrowth hormone secretagogue; synthetic hexapeptide containing D-amino acids and 2-naphthylalanine
Also listed asNNC 26-0161, Ipamorelin acetatePralmorelin, KP-102, Growth hormone releasing peptide-2
Molecular formulaC38H49N9O5C45H55N9O6
Molecular weight711.9 g/mol818.0 g/mol
CAS170851-70-4158861-67-7
PubChem CID98316596918245
Sequence lengthDescribed structurally, not as a residue listDescribed structurally, not as a residue list
Data caveatNone recordedPubChem's GHRP-6 record (CID 4345065) carries the synonym “GHRP-2 Acetate”. Full caveat
United States regulatory status
StatusFDA compounding Category 2FDA compounding Category 2
FDA applicationNone recordedNone recorded
CompoundingOn FDA's active 503B Category 2 list (added 29 September 2023).On FDA's active 503B Category 2 list for injectable and nasal routes (added 29 September 2023).
WADANamed at S2.2.4 among growth hormone secretagogues. Prohibited at all times; non-Specified.Named at S2.2.4 among GH-releasing peptides, as “GHRP-2 (pralmorelin)”. Prohibited at all times.
Research profile
Research purposeSelective GH secretagogue pharmacologyNo plain-English profile recorded
Proposed mechanismAgonist at the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, producing growth-hormone release. It acts at a different receptor from GHRH analogues such as tesamorelin.No plain-English profile recorded
Human evidenceNo approved product. Human data are early pharmacology rather than Phase 3 efficacy trials; Therapept indexes no approved label and no completed efficacy programme.No plain-English profile recorded
Evidence tierPreclinical models; no human efficacy trial indexedNo plain-English profile recorded
Known safety concerns
  • On FDA's Category 2 table for bulk substances that may present significant safety risks in compounding, with published immunogenicity and characterisation concerns.
  • Named on the WADA Prohibited List as a growth-hormone secretagogue.
  • Long-term endocrine effects of repeated use are not characterised in controlled trials.
No plain-English profile recorded
Evidence gaps
  • Controlled human efficacy and safety data.
  • Whether receptor selectivity translates into a better clinical profile.
  • Any lawful supply chain for human use.
No plain-English profile recorded
Head-to-head evidenceNo published head-to-head efficacy trial against tesamorelin or CJC-1295.No plain-English profile recorded
Named pathwaysGhrelin receptor (GHS-R1a) · Pituitary GH release · IGF-1No plain-English profile recorded
Evidence on file
Records
Human-interventional records10
Human-observational records00
Animal records10
In-vitro records00
Reviews10
Regulatory documents20
Earliest indexed1998Not recorded
Latest indexed2026Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.